TCRT (Alaunos Therapeutics) PS Ratio: (As of Jul. 06, 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.08
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alaunos Therapeutics's share price is $2.08. Alaunos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Alaunos Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Alaunos Therapeutics's PS Ratio or its related term are showing as below:

TCRT' s PS Ratio Range Over the Past 10 Years
Min: 9.07   Med: 681.18   Max: 6588.75
Current: 2080

During the past 13 years, Alaunos Therapeutics's highest PS Ratio was 6588.75. The lowest was 9.07. And the median was 681.18.

TCRT's PS Ratio is ranked worse than
97.31% of 929 companies
in the Biotechnology industry
Industry Median: 9.91 vs TCRT: 2080.00

Alaunos Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Warning Sign:

Alaunos Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Alaunos Therapeutics was -83.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -88.60% per year.

During the past 13 years, Alaunos Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 78.20% per year. The lowest was -88.60% per year. And the median was 16.35% per year.

Back to Basics: PS Ratio


Alaunos Therapeutics  (NAS:TCRT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Alaunos Therapeutics PS Ratio Related Terms


Alaunos Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics PS Ratio Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 586.02 48.25 3,535.00 317.50 1,076.67

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 245.00 1,616.67 803.33 1,076.67 0.00

TCRT vs DRMA, MBIO, ELAB: PS Ratio Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's PS Ratio falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Alaunos Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.08/0.001
=

Alaunos Therapeutics's Share Price of today is $2.08.
Alaunos Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • PS Ratio:
  • GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$0.68
GF Value